← back to search

Rainer Fietkau

Immunomedics (Germany) · DE
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Diagnosis and Treatment, Colorectal and Anal Carcinomas, Colorectal Cancer Surgical Treatments, and Lung Cancer Treatments and Mutations.
h-index
44
citations
17,229
works
263
NIH funding
primary concept
Medicine
email

Recent publications

Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial
˜The œLancet. Gastroenterology & hepatology 2025cited by 24position: middledoi
De-intensification of postoperative radiotherapy in head and neck cancer irrespective of human papillomavirus status—results of a prospective multicenter phase II trial (DIREKHT Trial)
Frontiers in Oncology 2024cited by 13position: lastdoi
The health-related quality of life of sarcoma patients treated with neoadjuvant versus adjuvant radiotherapy – Results of a multi-center observational study
Radiotherapy and Oncology 2023cited by 2position: middledoi
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Journal of Thoracic Oncology 2022cited by 219position: middledoi
Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.
Journal of Clinical Oncology 2022cited by 114position: firstdoi
DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis
Strahlentherapie und Onkologie 2022cited by 46position: middledoi
DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment
Strahlentherapie und Onkologie 2022cited by 41position: middledoi
Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment
Cancers 2022cited by 40position: middledoi
Neoadjuvant Therapy for Resectable Pancreatic Cancer
Annals of Surgery 2021cited by 81position: middledoi
1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Annals of Oncology 2021cited by 18position: middledoi
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
Journal for ImmunoTherapy of Cancer 2020cited by 87position: lastdoi
Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial
Annals of Oncology 2018cited by 112position: middledoi
Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial
Annals of Oncology 2018cited by 32position: middledoi
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
The Lancet Oncology 2015cited by 722position: middledoi
Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients
Annals of Oncology 2015cited by 129position: middledoi
Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial
Journal of Clinical Oncology 2014cited by 455position: middledoi
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
Strahlentherapie und Onkologie 2014cited by 329position: middledoi
Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years
Journal of Clinical Oncology 2012cited by 2,109position: middledoi
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial
The Lancet Oncology 2012cited by 698position: middledoi
Substantially Improved Outcome of Adult Burkitt Non-Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial
Blood 2012cited by 10position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Claus Rödel · Goethe University Frankfurt7 papers (2012–2025)Torsten Liersch · Universitätsmedizin Göttingen6 papers (2012–2018)Gerhard G. Grabenbauer · Friedrich-Alexander-Universität Erlangen-Nürnberg6 papers (2012–2018)Werner Hohenberger · Universitätsklinikum Erlangen6 papers (2012–2018)Rolf Sauer · Universitätsklinikum Erlangen6 papers (2012–2018)Michael Ghadimi · Universitätsmedizin Göttingen5 papers (2014–2022)Hans-Rudolf Raab · Krebsregister Saarland4 papers (2012–2015)Sabine Semrau · National Center for Tumor Diseases4 papers (2015–2023)Emmanouil Fokas · DKFZ-ZMBH Alliance4 papers (2014–2025)Christian Wittekind · Leipzig University4 papers (2012–2015)Torsten Hothorn · Vienna University of Economics and Business4 papers (2012–2018)Ullrich Graeven · Kliniken Maria Hilf4 papers (2012–2018)Robert Grützmann · Friedrich-Alexander-Universität Erlangen-Nürnberg3 papers (2018–2023)Gunnar Folprecht · Helmholtz-Zentrum Dresden-Rossendorf3 papers (2012–2018)Susanne Merkel · University of Southampton3 papers (2012–2014)Henriette Golcher · National Center for Tumor Diseases3 papers (2014–2023)Heinz Becker · Philipps University of Marburg3 papers (2012–2014)Clemens F. Hess · Universitätsmedizin Göttingen3 papers (2012–2014)Anke Schlenska‐Lange · Krankenhaus Barmherzige Brüder2 papers (2012–2015)Jair Bar · Tel Aviv University2 papers (2021–2022)